Given the shift toward personalized medicine amid an aging population and rising disease burden globally, continued advancements such as gene editing technologies, synthetic biology, and molecular diagnostics, and regulatory support and fast-track approvals by agencies like the FDA and EMA, the biotech industry is well-placed for long-term growth.
Considering the industry’s bright outlook, it could be wise to invest in fundamentally sound biotech stocks Genmab A/S (GMAB), Halozyme Therapeutics, Inc. (HALO), and Vertex Pharmaceuticals Incorporated (VRTX) for potential gains.
